|1.||Di Leo, Angelo: 6 articles (10/2013 - 08/2003)|
|2.||Di Leo, A: 5 articles (12/2013 - 05/2001)|
|3.||Larsimont, D: 5 articles (12/2013 - 05/2001)|
|4.||Sehested, Maxwell: 5 articles (02/2010 - 06/2002)|
|5.||Cardoso, F: 4 articles (12/2013 - 05/2001)|
|6.||Durbecq, V: 4 articles (12/2013 - 01/2004)|
|7.||Larsimont, Denis: 4 articles (10/2013 - 10/2004)|
|8.||Koren, Rumelia: 4 articles (12/2008 - 08/2004)|
|9.||Paesmans, M: 4 articles (08/2004 - 05/2001)|
|10.||Jensen, Peter B: 4 articles (06/2004 - 06/2002)|
05/01/2005 - "The aim of our study was to evaluate the proliferative MIB-1 and topoisomerase II-alpha markers in both oncocytic and non-oncocytic epithelial thyroid tumors. "
06/01/2015 - "Our results suggest that in these tumors, selected marker staining seems to correlate with tumor differentiation; that is, well-differentiated tumors as a group stained with EMA and AR, and palisaded areas demonstrated consistent p53, topoisomerase II alpha and p27(kip1) staining. "
06/01/2015 - "Most of the tumors with well-differentiated palisaded areas demonstrated positive staining for topoisomerase II alpha, p27(kip1), and p53, with positive staining in tumoral basaloid areas (22/30). "
03/01/2014 - "Using positional proteomics in human tumor cells, we identified the nuclear enzyme topoisomerase II alpha (topoIIα) as a physiological substrate of GrM. "
01/01/2014 - "The surexpression of topoisomerase II alpha was associated within increased tumor stage. "
|2.||Breast Neoplasms (Breast Cancer)
07/01/2010 - "The objective of this study was to develop a new real time PCR-based method for quantitative detection of topoisomerase II alpha (TOP2A) aberrations and to evaluate its clinical utility in breast cancer. "
06/01/2010 - "This study applied TMA in order to analyse the topoisomerase II alpha status in breast cancer and to elucidate its relationship in breast cancer biology. "
04/01/2004 - "In this study, we examined whether TOP2A gene amplification is an appropriate marker for identifying breast tumors expressing high levels of topoisomerase II alpha. "
06/01/2010 - "Topoisomerase II alpha expression failed to demonstrate prognostic value in patients with breast cancer."
06/01/2010 - "Archived tissue specimens from 94 patients with primary invasive breast cancer were selected and the topoisomerase II alpha expression was analysed by TMA. "
|3.||Glioblastoma (Glioblastoma Multiforme)
05/01/2003 - "MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma."
05/01/2003 - "Our study showed that both MIB-1 and topoisomerase II alpha could help predict long-term survival of patients with glioblastomas. "
06/19/2012 - "Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells."
05/01/2003 - "We studied the MIB-1 labeling index (LI) and DNA topoisomerase II alpha LI of glioblastomas from 34 patients who lived for more than 2 years after diagnosis and of glioblastomas from 34 age- and sex-matched control patients who died within 2 years of diagnosis. "
12/01/2000 - "Glial tumor cells in all glioblastomas showed constant up-regulation of LRP, MRP, and topoisomerase II alpha. "
|4.||Colonic Neoplasms (Colon Cancer)
04/01/1999 - "To begin to correlate biologic response to Topo I drugs with the molecular characteristics of the neoplasm, we studied Topo I and DNA topoisomerase II-alpha (Topo II-alpha) expression in 29 cases of colon cancer. "
08/23/1996 - "Effect of acute and chronic intermittent hypoxia on DNA topoisomerase II alpha expression and mitomycin C-induced DNA damage and cytotoxicity in human colon cancer cells."
12/10/1999 - "We also found that a transient co-transfection with a DNA topoisomerase II alpha promoter-luciferase plasmid and an antisense YB-1 expression construct resulted in a significant reduction of the promoter activity in KM12C human colon cancer cells. "
|5.||Wounds and Injuries (Trauma)
02/28/2010 - "Using the model of extravasation in a dexrazoxane-resistant transgenic mouse with a heterozygous mutation in the topoisomerase II alpha gene (Top2a(Y165S/+)), we found that dexrazoxane provided a protection against anthracycline-induced skin wounds that was indistinguishable from that found in wildtype mice. "
|1.||Type II DNA Topoisomerases (Topoisomerase II)
|3.||Messenger RNA (mRNA)
|6.||A-Form DNA (A-DNA)
|8.||trioctyl phosphine oxide (TOPO)
|1.||Drug Therapy (Chemotherapy)
|4.||Combined Modality Therapy